Latest Recruitment News

Tanami Gold has secured $70.5 million through a fully underwritten rights issue to fund its Central Tanami Project development, including a major underground decline and resumed drilling at Jims Gold Mine.

Careteq Limited (ASX: CTQ) has confirmed it will maintain its ASX listing after selling its Embedded Health Solutions subsidiary, shifting its strategic focus entirely to its HMR Referrals platform. The company reported positive operating cash flow in the March quarter and outlined plans to expand its pharmacist and GP networks while exploring AI and adjacent healthcare opportunities.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Optiscan Imaging has fast-tracked Stage 2 of its pioneering head and neck cancer imaging study, moving into live intraoperative imaging ahead of schedule. This advancement supports FDA regulatory efforts and enhances the company’s AI imaging development.

Tivan Limited has appointed Robert Gerrard as CEO (Australia), elevated Dr Ellin Lede to the Board, and named Brendon Nicol as CTO to sharpen its leadership as it moves towards key project milestones at Speewah and Molyhil.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

HiTech Group Australia is acquiring Hudson Global Resources’ Australian operations for $7 million, significantly broadening its footprint and diversifying services beyond ICT recruitment.

Neurizon Therapeutics has completed enrolment for Regimen I of its HEALEY ALS Platform Trial in under five months, speeding up topline data release to late Q2 2027 and materially de-risking its lead clinical program.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

Ava Risk Group expects FY2026 revenue around $29 million, below prior guidance, due to delayed orders mainly in the Middle East and North America. Despite this, sales intake exceeded revenue, underpinning a strong backlog and positive EBITDA.